Sharjeel Usmani1, Fahad Marafi1,2, Abdulredha Esmail1, Najeeb Ahmed3. 1. 1 Department of Nuclear Medicine, Kuwait Cancer Control Center (KCCC) , Khaitan , Kuwait. 2. Department of Nuclear Medicine , Jaber Al-Ahmad Molecular Imaging Center, Kuwait , Kuwait. 3. 3 Radiology, Jack Brignall PET/CT Centre, Castle Hill Hosptial , Cottingham , UK.
Abstract
OBJECTIVE: Os acromiale (OA) is a failure of complete fusion of the acromial process. It is usually asymptomatic and discovered incidentally. OA can contribute to shoulder impingement symptoms and rotator cuff tears. 18F Sodium Fluoride (NaF) Positron Emission Tomography -CT (PET-CT) is an emerging and highly sensitive modality for oncological skeletal staging, and can show a variety of non-malignant uptake. We have analysed the relationship between 18F-NaF uptake in OA and associated symptoms of shoulder pain. METHODS: Study population included 21 patients (mean age 60.2 ± 12 years; 13 females and 8 males) with OA who underwent PET-CT scan by injecting 2.22 MBq kg-1 of 18F-NaF. The relationship between 18F-NaF uptake and OA as a cause of pain was analysed. A 3-point grading system was used to evaluate uptake of 18F-NaF. RESULTS: In total 27 OA (12 symptomatic and 15 asymptomatic) were enrolled. All symptomatic OA showed focal increase tracer uptake of Grade 2, while asymptomatic OA did not have significant activity Grade 0 (n = 11) and Grade 1 (n = 4). CONCLUSION: 18F-NaF PET-CT appears to be a useful adjunct in the assessment of symptomatic OA with its particular strength being its high negative predictive value. Advances in knowledge: 18F-NaF PET-CT may be used as an ancillary tool for identifying symptomatic OA as a cause of shoulder pain in cases where other obvious causes of shoulder pain have been excluded.
OBJECTIVE: Os acromiale (OA) is a failure of complete fusion of the acromial process. It is usually asymptomatic and discovered incidentally. OA can contribute to shoulder impingement symptoms and rotator cuff tears. 18FSodium Fluoride (NaF) Positron Emission Tomography -CT (PET-CT) is an emerging and highly sensitive modality for oncological skeletal staging, and can show a variety of non-malignant uptake. We have analysed the relationship between 18F-NaF uptake in OA and associated symptoms of shoulder pain. METHODS: Study population included 21 patients (mean age 60.2 ± 12 years; 13 females and 8 males) with OA who underwent PET-CT scan by injecting 2.22 MBq kg-1 of 18F-NaF. The relationship between 18F-NaF uptake and OA as a cause of pain was analysed. A 3-point grading system was used to evaluate uptake of 18F-NaF. RESULTS: In total 27 OA (12 symptomatic and 15 asymptomatic) were enrolled. All symptomatic OA showed focal increase tracer uptake of Grade 2, while asymptomatic OA did not have significant activity Grade 0 (n = 11) and Grade 1 (n = 4). CONCLUSION:18F-NaF PET-CT appears to be a useful adjunct in the assessment of symptomatic OA with its particular strength being its high negative predictive value. Advances in knowledge: 18F-NaF PET-CT may be used as an ancillary tool for identifying symptomatic OA as a cause of shoulder pain in cases where other obvious causes of shoulder pain have been excluded.
Authors: Ivan Jambor; Anna Kuisma; Susan Ramadan; Riikka Huovinen; Minna Sandell; Sami Kajander; Jukka Kemppainen; Esa Kauppila; Joakim Auren; Harri Merisaari; Jani Saunavaara; Tommi Noponen; Heikki Minn; Hannu J Aronen; Marko Seppänen Journal: Acta Oncol Date: 2015-04-02 Impact factor: 4.089
Authors: M Beheshti; F M Mottaghy; F Paycha; F F F Behrendt; T Van den Wyngaert; I Fogelman; K Strobel; M Celli; S Fanti; F Giammarile; B Krause; W Langsteger Journal: Eur J Nucl Med Mol Imaging Date: 2015-07-23 Impact factor: 9.236
Authors: Johan Löfgren; Jann Mortensen; Sine H Rasmussen; Claus Madsen; Annika Loft; Adam E Hansen; Peter Oturai; Karl Erik Jensen; Mette Louise Mørk; Michala Reichkendler; Liselotte Højgaard; Barbara M Fischer Journal: J Nucl Med Date: 2017-08-10 Impact factor: 10.057
Authors: Bruce E Hillner; Barry A Siegel; Lucy Hanna; Fenghai Duan; Anthony F Shields; R Edward Coleman Journal: J Nucl Med Date: 2014-02-27 Impact factor: 10.057